Jacob Rotmensch to Disease-Free Survival
This is a "connection" page, showing publications Jacob Rotmensch has written about Disease-Free Survival.
Connection Strength
0.169
-
A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol. 2016 Jan; 140(1):48-52.
Score: 0.030
-
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
Score: 0.026
-
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
Score: 0.024
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 01; 29(16):2259-65.
Score: 0.022
-
Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol. 2011 Jun 01; 121(3):581-5.
Score: 0.022
-
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4.
Score: 0.020
-
Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9.
Score: 0.013
-
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.
Score: 0.012